Summary

Global In-Vitro Diagnostics (IVD) Market Research Report by Product (Reagents & Kits, Instruments [Fully Automated Instruments, Semi-Automated Instruments], Accessories), by Technology (Immunoassay/Immunochemistry [Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Rapid Test, Western Blotting, Others], Clinical Chemistry, Molecular Diagnostics [Polymerase Chain Reaction, Hybridization, Microarray, DNA Sequencing & Next-Generation Sequencing, Others], Hemostasis, Hematology, Others), by Application (Allergy Diseases, Autoimmune Diseases, Others), by End User (Hospitals, Laboratories, Point-of-Care Testing, Research and Academic Institutions, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2035

The Global In-Vitro Diagnostics (IVD) Market report is projected to grow from USD 91,452.13 million in 2025 to USD 1,61,511.99 million by 2035, registering a CAGR of 5.52% during 2025–2035. The growth reflects rising demand for advanced diagnostic solutions and expanding healthcare testing requirements worldwide.

Rapid and Decentralized Diagnosis
Faster and trustworthy detection and diagnosis at the patient's location or within a short distance are being made possible by the increasing use of point-of-care testing (POCT), which in turn is boosting the Global In-Vitro Diagnostics (IVD) Market. With these methods turning diagnosis around quickly, the time available for decisions is increasing and thus clinical outcomes are improved. These developments are not only allowing the expansion of POCT within hospitals and pharmacies but also to the realm of emergency care, home-testing settings.

Market Segmentation Overview
By Product
- Reagents & Kits: Increasing test volumes boost reagent consumption.
- Fully Automated Instruments: Automated platforms enhance accuracy and operational efficiency.
- Semi-Automated Instruments: Semi-automated systems offer flexible testing capabilities.
- Accessories: Essential accessories support smooth diagnostic operations.
By Technology
- Immunoassay/Immunochemistry: Broad applications make immunodiagnostics highly relevant.
- Enzyme-Linked Immunosorbent Assay: ELISA enables reliable biomarker and antibody detection.
- Radioimmunoassay: Sensitive detection supports specialized laboratory applications.
- Rapid Test: Faster results strengthen adoption across decentralized settings.
- Western Blotting: Western blotting supports confirmatory diagnostic testing.
- Others: New methods continue expanding immunodiagnostic applications.
- Clinical Chemistry: High routine testing volumes sustain demand.
- Molecular Diagnostics: Precision testing drives molecular diagnostic adoption.
- Polymerase Chain Reaction: PCR remains important for rapid pathogen detection.
- Hybridization: Hybridization enables targeted genetic and molecular analysis.
- Microarray: Multiplex testing supports broader diagnostic applications.
- DNA Sequencing & Next-Generation Sequencing: Advanced sequencing expands genomic testing capabilities.
- Others: Emerging techniques strengthen molecular diagnostic offerings.
- Hemostasis: Rising coagulation testing needs support segment growth.
- Hematology: Increasing blood testing maintains hematology demand.
- Others: Specialized technologies address varied diagnostic requirements.
By Application
- Allergy Diseases: Increasing allergy prevalence drives diagnostic testing demand.
- Autoimmune Diseases: Greater disease awareness encourages autoimmune testing.
- Others: Additional diseases contribute to IVD adoption.
By End User
- Hospitals: Expanding diagnostic workloads sustain hospital-based IVD demand.
- Laboratories: Laboratories require efficient and reliable testing solutions.
- Point-of-Care Testing: POCT enables faster diagnosis outside laboratories.
- Research and Academic Institutions: Research programs encourage advanced diagnostic technology adoption.
- Others: Diverse healthcare settings support wider IVD utilization.

Regional Analysis
North America remained the biggest contributor to the Global In-Vitro Diagnostics (IVD) Market in 2025 because it had a very developed healthcare infrastructure. Asia-Pacific region is anticipated to grow at the fastest pace registering a CAGR of 6.95% during the forecast period.

Advancing Alzheimer’s Diagnostics
In June 2026, Sysmex Corporation expanded its diagnostic capabilities as Sysmex Europe SE announced the availability of the HISCL automated immunoassay system for Alzheimer’s blood biomarker testing. PCR, digital PCR, and various nucleic acid-based technologies are being quickly adopted to such an extent that they have been playing a role in reinforcing of the IVD market.

Precision-Driven Molecular Diagnostics
Demand for POCT is increasing with hospitals wanting to shorten their lab reporting turnaround times thereby speeding up diagnosis. Moreover with POCT, there is less need of sending patients and samples to the lab since they are capable of detecting the disease at the spot. Thus, POCT is contributing significantly to the diagnostics market which is expected to grow at an average rate of 17.2 percent to cross $55 billion by 2027.

Key Report Attributes
- Market Size 2025: USD 91,452.13 Million
- Market Size 2035: USD 1,61,511.99 Million
- CAGR (2025-2035): 5.52%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Product: Reagents & Kits - 6.14%, Instruments - 4.36%.
- By Technology: Immunoassay/Immunochemistry - 6.07%, Clinical Chemistry - 4.99%.
- By Application: Allergy Diseases - 3.68%, Autoimmune Diseases - 4.55%.
- By End User: Hospitals - 4.94%, Laboratories - 6.13%.

Reasons to Buy
- Analyze global In-Vitro Diagnostics market demand across healthcare applications.
- Assess diagnostic technology advances supporting IVD market growth.
- Evaluate molecular diagnostics and immunoassay adoption trends globally.
- Identify point-of-care testing opportunities expanding IVD market demand.
- Understand chronic disease testing needs shaping future IVD growth.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 19
2 MARKET INTRODUCTION 21
2.1 DEFINITION 21
2.2 SCOPE OF THE STUDY 21
2.3 Research Objective 21
2.4 MARKET STRUCTURE 22
3 RESEARCH METHODOLOGY 23
3.1 Overview 23
3.2 DATA flow 25
3.2.1 DATA MINING PROCESS 25
3.3 Purchased Database: 26
3.4 Secondary Sources: 27
3.4.1 SECONDARY RESEARCH DATA FLOW: 28
3.5 Primary Research: 29
3.5.1 PRIMARY RESEARCH DATA FLOW: 30
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 31
3.5.3 APPROACHES FOR MARKET SIZE ESTIMATION: 32
3.5.4 REVENUE ANALYSIS APPROACH 32
3.6 Data forecasting 33
3.6.1 DATA FORECASTING TYPE 33
3.7 Data modeling 34
3.7.1 MICROECONOMIC FACTOR ANALYSIS: 34
3.7.2 DATA MODELING: 35
3.8 Teams and Analyst Contribution 37
4 MARKET DYNAMICS 39
4.1 Introduction 39
4.2 Drivers 40
4.2.1 HIGH PREVALENCE OF CHRONIC AND ALLERGY DISEASES 40
4.2.2 INCREASING ADOPTION OF POINT-OF-CARE TESTING (POCT) 41
4.2.3 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 41
4.2.4 GROWING DEMAND FOR EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE 42
4.3 Restraints 43
4.3.1 STRINGENT REGULATORY REQUIREMENTS 43
4.3.2 HIGH COST OF DIAGNOSTIC INSTRUMENTS AND REAGENTS 44
4.3.3 REIMBURSEMENT AND PRICING CHALLENGES 45
4.4 Opportunities 46
4.4.1 INCREASING ADOPTION OF PCR, NGS, AND OTHER MOLECULAR TESTING TECHNOLOGIES FOR INFECTIOUS DISEASES, ONCOLOGY, AND GENETIC DISORDER DETECTION 46
4.4.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL DIAGNOSTICS 46
5 MARKET FACTOR ANALYSIS 48
5.1 Regulatory Environment & Compliance 48
5.2 Technological Trends & Innovation 50
5.3 Patient Demographics & Disease Burdens 52
5.4 Pricing Analysis & Reimbursement Dynamics 52
5.4.1 PRICING ANALYSIS 52
5.4.1.1.1 Pricing Analysis, By Product 52
5.4.2 REIMBURSEMENT DYNAMICS 52
5.5 Market Entry & Exit Barriers 53
5.5.1 BARRIERS TO ENTRY 53
5.5.2 BARRIERS TO EXIT 53
5.6 Partnerships & Collaborations 54
5.7 Consumer & Healthcare Provider Preferences 55
5.7.1 CONSUMER PREFERENCES 55
5.7.2 HEALTHCARE PROVIDER PREFERENCES 55
5.8 PESTLE ANALYSIS 56
5.8.1 POLITICAL FACTORS 56
5.8.2 ECONOMIC FACTORS 56
5.8.3 SOCIAL FACTORS 56
5.8.4 TECHNOLOGICAL FACTORS 56
5.8.5 LEGAL FACTORS 57
5.8.6 ENVIRONMENTAL FACTORS 57
5.9 Porter's Five Forces Model 58
5.9.1 THREAT OF NEW ENTRANTS 58
5.9.2 BARGAINING POWER OF SUPPLIERS 59
5.9.3 THREAT OF SUBSTITUTES 59
5.9.4 BARGAINING POWER OF BUYERS 59
5.9.5 INTENSITY OF RIVALRY 59
5.10 Investment & Funding Scenarios 60
6 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT 62
6.1 Overview 62
7 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY 65
7.1 Overview 65
8 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION 69
8.1 Overview 69
9 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER 72
9.1 Overview 72
10 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY REGION 75
10.1 Overview 75
10.2 NORTH AMERICA 76
10.2.1 US 81
10.2.2 CANADA 84
10.3 europe 88
10.3.1 GERMANY 93
10.3.2 FRANCE 96
10.3.3 UK 100
10.3.4 ITALY 103
10.3.5 SPAIN 107
10.3.6 REST OF EUROPE 110
10.4 asia pacific 114
10.4.1 CHINA 119
10.4.2 INDIA 123
10.4.3 JAPAN 126
10.4.4 SOUTH KOREA 129
10.4.5 REST OF ASIA PACIFIC 133
10.5 REST OF THE WORLD 137
10.5.1 MIDDLE EAST & AFRICA 142
10.5.2 SOUTH AMERICA 145
11 COMPETITIVE LANDSCAPE 150
11.1 Introduction 150
11.2 Market Share Analysis, 2025 150
11.3 competitor dashboard 151
11.4 Public Players Stock Summary 152
11.5 Comparative Analysis: Key Players Finanical 152
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 153
11.6.1 PRODUCT LAUNCH 153
11.6.2 PRODUCT APPROVAL 156
11.6.3 PRODUCT AVAILABILITY 157
11.6.4 PARTNERSHIP 158
11.6.5 AGREEMENT 159
11.6.6 SUSTAINABILITY 159
11.6.7 FACILITY EXPANSION 160
11.6.8 INVESTMENT 160
11.6.9 PRODUCT EXPANSION 161
12 COMPANY PROFILES 162
12.1 F. Hoffmann-La Roche Ltd. 162
12.1.1 COMPANY OVERVIEW 162
12.1.2 FINANCIAL OVERVIEW 163
12.1.3 PRODUCTS OFFERED 163
12.1.4 KEY DEVELOPMENTS 165
12.1.5 SWOT ANALYSIS 167
12.1.6 KEY STRATEGIES 167
12.2 QIAGEN 168
12.2.1 COMPANY OVERVIEW 168
12.2.2 FINANCIAL OVERVIEW 169
12.2.3 PRODUCTS OFFERED 169
12.2.4 KEY DEVELOPMENTS 170
12.2.5 SWOT ANALYSIS 171
12.2.6 KEY STRATEGIES 172
12.3 Siemens Healthineers 173
12.3.1 COMPANY OVERVIEW 173
12.3.2 FINANCIAL OVERVIEW 174
12.3.3 PRODUCTS OFFERED 175
12.3.4 KEY DEVELOPMENTS 176
12.3.5 SWOT ANALYSIS 177
12.3.6 KEY STRATEGIES 177
12.4 Bio-Rad Laboratories, Inc. 178
12.4.1 COMPANY OVERVIEW 178
12.4.2 FINANCIAL OVERVIEW 179
12.4.3 PRODUCTS OFFERED 179
12.4.4 KEY DEVELOPMENTS 181
12.4.5 SWOT ANALYSIS 182
12.4.6 KEY STRATEGIES 183
12.5 Thermo Fisher Scientific Inc. 184
12.5.1 COMPANY OVERVIEW 184
12.5.2 FINANCIAL OVERVIEW 185
12.5.3 PRODUCTS OFFERED 185
12.5.4 KEY DEVELOPMENTS 186
12.5.5 SWOT ANALYSIS 187
12.5.6 KEY STRATEGIES 188
12.6 Sysmex Corporation 189
12.6.1 COMPANY OVERVIEW 189
12.6.2 FINANCIAL OVERVIEW 190
12.6.3 PRODUCTS OFFERED 190
12.6.4 KEY DEVELOPMENTS 192
12.6.5 KEY STRATEGIES 193
12.7 DiaSorin S.p.A. 194
12.7.1 COMPANY OVERVIEW 194
12.7.2 FINANCIAL OVERVIEW 195
12.7.3 PRODUCTS OFFERED 196
12.7.4 KEY DEVELOPMENTS 197
12.7.5 KEY STRATEGIES 198
12.8 Randox Laboratories Ltd. 199
12.8.1 COMPANY OVERVIEW 199
12.8.2 FINANCIAL OVERVIEW 199
12.8.3 PRODUCTS OFFERED 200
12.8.4 KEY DEVELOPMENTS 201
12.8.5 KEY STRATEGIES 201
12.9 Becton, Dickinson and Company 202
12.9.1 COMPANY OVERVIEW 202
12.9.2 FINANCIAL OVERVIEW 203
12.9.3 PRODUCTS OFFERED 204
12.9.4 KEY DEVELOPMENTS 204
12.9.5 KEY STRATEGIES 205
12.10 Illumina, Inc. 206
12.10.1 COMPANY OVERVIEW 206
12.10.2 FINANCIAL OVERVIEW 207
12.10.3 PRODUCTS OFFERED 208
12.10.4 KEY DEVELOPMENTS 208
12.10.5 KEY STRATEGIES 209
13 DATA CITATIONS 210

COMPANIES MENTIONED
F. Hoffmann-La Roche Ltd, Siemens Healthineers, Thermo Fisher Scientific Inc., Qiagen, Sysmex Corporation, Randox Laboratories Ltd., Illumina, Inc., Becton, Dickinson and Company, DiaSorin S.p.A., Bio-Rad Laboratories, Inc.

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET : STRUCTURE 22
FIGURE 2 GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2036) 40
FIGURE 3 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET DRIVER: IMPACT ANALYSIS 43
FIGURE 4 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET RESTRAINT: IMPACT ANALYSIS 45
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL IN VITRO DIAGNOSTICS (IVD) MARKET 58
FIGURE 6 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2025 & 2036 (USD MILLION) 62
FIGURE 7 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2025 & 2036 (USD MILLION) 63
FIGURE 8 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY PRODUCT TYPE, 2025 64
FIGURE 9 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2025 & 2036 (USD MILLION) 65
FIGURE 10 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2025 & 2036 (USD MILLION) 66
FIGURE 11 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY TECHNOLOGY, 2025 68
FIGURE 12 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2025 & 2036 (USD MILLION) 69
FIGURE 13 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2025 & 2036 (USD MILLION) 70
FIGURE 14 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY APPLICATION, 2025 71
FIGURE 15 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, END USER SEGMENT ATTRACTIVENESS, 2025 & 2036 (USD MILLION) 72
FIGURE 16 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2025 & 2036 (USD MILLION) 73
FIGURE 17 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY END USER, 2025 74
FIGURE 18 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY REGION, 2025 & 2036 (USD MILLION) 75
FIGURE 19 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY REGION, 2025 & 2036 (USD MILLION) 76
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: IN-VITRO DIAGNOSTICS (IVD) MARKET, 2019-2036 (USD MILLION) 76
FIGURE 21 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2025 & 2036 (USD MILLION) 77
FIGURE 22 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY COUNTRY, 2025 78
FIGURE 23 EUROPE MARKET ANALYSIS: IN-VITRO DIAGNOSTICS (IVD) MARKET, 2019-2036 (USD MILLION) 88
FIGURE 24 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2025 & 2036 (USD MILLION) 88
FIGURE 25 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY COUNTRY, 2025 89
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: IN-VITRO DIAGNOSTICS (IVD) MARKET, 2019-2036 (USD MILLION) 114
FIGURE 27 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2025 & 2036 (USD MILLION) 115
FIGURE 28 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY COUNTRY, 2025 116
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: IN-VITRO DIAGNOSTICS (IVD) MARKET, 2019-2036 (USD MILLION) 137
FIGURE 30 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2025 & 2036 (USD MILLION) 137
FIGURE 31 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET SHARE (%), BY COUNTRY, 2025 138
FIGURE 32 GLOBAL IN-VITRO DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 150
FIGURE 33 COMPETITOR DASHBOARD: GLOBAL IN-VITRO DIAGNOSTICS MARKET 151
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW 163
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 167
FIGURE 36 QIAGEN: FINANCIAL OVERVIEW SNAPSHOT 169
FIGURE 37 QIAGEN: SWOT ANALYSIS 171
FIGURE 38 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT 174
FIGURE 39 SIEMENS HEALTHINEERS: SWOT ANALYSIS 177
FIGURE 40 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 179
FIGURE 41 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 182
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 185
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 187
FIGURE 44 SYSMEX CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 190
FIGURE 45 DIASORIN S.P.A.: FINANCIAL OVERVIEW SNAPSHOT 195
FIGURE 46 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 203
FIGURE 47 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT 207

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 36
TABLE 2 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 63
TABLE 3 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 63
TABLE 4 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 66
TABLE 5 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 67
TABLE 6 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 67
TABLE 7 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 70
TABLE 8 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 73
TABLE 9 GLOBAL IN-VITRO DIAGNOSTICS (IVD) MARKET, BY REGION, 2019-2036 (USD MILLION) 75
TABLE 10 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 77
TABLE 11 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 78
TABLE 12 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 78
TABLE 13 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 79
TABLE 14 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 79
TABLE 15 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 80
TABLE 16 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 80
TABLE 17 NORTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 81
TABLE 18 US IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 81
TABLE 19 US IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 82
TABLE 20 US IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 82
TABLE 21 US IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 83
TABLE 22 US IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 83
TABLE 23 US IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 84
TABLE 24 US IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 84
TABLE 25 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 84
TABLE 26 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 85
TABLE 27 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 85
TABLE 28 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 86
TABLE 29 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 86
TABLE 30 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 87
TABLE 31 CANADA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 87
TABLE 32 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 89
TABLE 33 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 89
TABLE 34 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 90
TABLE 35 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 90
TABLE 36 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 91
TABLE 37 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 91
TABLE 38 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 92
TABLE 39 EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 92
TABLE 40 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 93
TABLE 41 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 93
TABLE 42 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 94
TABLE 43 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 94
TABLE 44 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 95
TABLE 45 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 95
TABLE 46 GERMANY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 96
TABLE 47 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 96
TABLE 48 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 97
TABLE 49 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 97
TABLE 50 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 98
TABLE 51 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 98
TABLE 52 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 99
TABLE 53 FRANCE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 99
TABLE 54 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 100
TABLE 55 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 100
TABLE 56 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 101
TABLE 57 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 101
TABLE 58 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 102
TABLE 59 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 102
TABLE 60 UK IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 103
TABLE 61 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 103
TABLE 62 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 104
TABLE 63 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 104
TABLE 64 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 105
TABLE 65 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 105
TABLE 66 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 106
TABLE 67 ITALY IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 106
TABLE 68 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 107
TABLE 69 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 107
TABLE 70 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 108
TABLE 71 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 108
TABLE 72 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 109
TABLE 73 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 109
TABLE 74 SPAIN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 110
TABLE 75 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 110
TABLE 76 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 111
TABLE 77 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 111
TABLE 78 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 112
TABLE 79 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 112
TABLE 80 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 113
TABLE 81 REST OF EUROPE IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 113
TABLE 82 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 115
TABLE 83 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 116
TABLE 84 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 116
TABLE 85 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 117
TABLE 86 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 117
TABLE 87 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 118
TABLE 88 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 118
TABLE 89 ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 119
TABLE 90 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 119
TABLE 91 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 120
TABLE 92 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 120
TABLE 93 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 121
TABLE 94 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 121
TABLE 95 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 122
TABLE 96 CHINA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 122
TABLE 97 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 123
TABLE 98 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 123
TABLE 99 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 124
TABLE 100 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 124
TABLE 101 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 125
TABLE 102 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 125
TABLE 103 INDIA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 126
TABLE 104 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 126
TABLE 105 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 127
TABLE 106 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 127
TABLE 107 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE, 2019-2036 (USD MILLION) 128
TABLE 108 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 128
TABLE 109 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 129
TABLE 110 JAPAN IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 129
TABLE 111 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 129
TABLE 112 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 130
TABLE 113 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 130
TABLE 114 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 131
TABLE 115 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 131
TABLE 116 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 132
TABLE 117 SOUTH KOREA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 132
TABLE 118 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 133
TABLE 119 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 133
TABLE 120 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 134
TABLE 121 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 134
TABLE 122 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019-2036 (USD MILLION) 135
TABLE 123 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 135
TABLE 124 REST OF ASIA PACIFIC IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 136
TABLE 125 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 138
TABLE 126 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 138
TABLE 127 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 139
TABLE 128 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 139
TABLE 129 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 140
TABLE 130 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019-2036 (USD MILLION) 140
TABLE 131 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 141
TABLE 132 REST OF THE WORLD IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 141
TABLE 133 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 142
TABLE 134 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 142
TABLE 135 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 143
TABLE 136 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 143
TABLE 137 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019-2036 (USD MILLION) 144
TABLE 138 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 144
TABLE 139 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 145
TABLE 140 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY PRODUCT, 2019-2036 (USD MILLION) 145
TABLE 141 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2036 (USD MILLION) 146
TABLE 142 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY TECHNOLOGY, 2019-2036 (USD MILLION) 146
TABLE 143 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR IMMUNOASSAY/IMMUNOCHEMISTRY,
BY TYPE, 2019-2036 (USD MILLION) 147
TABLE 144 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019-2036 (USD MILLION) 147
TABLE 145 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY APPLICATION, 2019-2036 (USD MILLION) 148
TABLE 146 SOUTH AMERICA IN-VITRO DIAGNOSTICS (IVD) MARKET, BY END USER, 2019-2036 (USD MILLION) 148
TABLE 147 PRODUCT LAUNCH 153
TABLE 148 PRODUCT APPROVAL 156
TABLE 149 PRODUCT AVAILABILITY 157
TABLE 150 PARTNERSHIP 158
TABLE 151 AGREEMENT 159
TABLE 152 SUSTAINABILITY 159
TABLE 153 FACILITY EXPANSION 160
TABLE 154 INVESTMENT 160
TABLE 155 PRODUCT EXPANSION 161
TABLE 156 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 163
TABLE 157 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS 165
TABLE 158 QIAGEN: PRODUCTS OFFERED 169
TABLE 159 QIAGEN: KEY DEVELOPMENTS 170
TABLE 160 SIEMENS HEALTHINEERS: PRODUCTS OFFERED 175
TABLE 161 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS 176
TABLE 162 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 179
TABLE 163 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 181
TABLE 164 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 185
TABLE 165 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 186
TABLE 166 SYSMEX CORPORATION: PRODUCTS OFFERED 190
TABLE 167 SYSMEX CORPORATION: KEY DEVELOPMENTS 192
TABLE 168 DIASORIN S.P.A.: PRODUCTS OFFERED 196
TABLE 169 DIASORIN S.P.A.: KEY DEVELOPMENTS 197
TABLE 170 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED 200
TABLE 171 RANDOX LABORATORIES LTD.: KEY DEVELOPMENTS 201
TABLE 172 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 204
TABLE 173 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS 204
TABLE 174 ILLUMINA, INC.: PRODUCTS OFFERED 208
TABLE 175 ILLUMINA, INC.: PRODUCTS OFFERED 208